Market research
PLRX Pliant Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 71M
- P/E ratio
- Not available
- Analyst target
- 2.5
- Dividend yield
- Not available
- Beta
- 1.27
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US7291391057
- Market cap
- 71M
- P/E ratio
- Not available
- Analyst target
- 2.5
- Dividend yield
- Not available
- Beta
- 1.27
About
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PLRX discussion.
5 years, 4 months ago
Pliant Therapeutics, Inc is currently in a long term downtrend where the price is trading 9.5% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.2.
Based on the above factors, Pliant Therapeutics, Inc gets an overall score of 1/5.